Physician profile
Mary E Pugmire
NPI 1508964701
$1,958.19
in general payments reported to CMS, 2019-2025
29 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $240 · 2021: $338 · 2022: $271 · 2023: $179 · 2024: $246 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.90 | 2019-2023 | |
| Biogen, INC. | $256.60 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $158.17 | 2021-2022 | |
| Pfizer INC. | $132.44 | 2019-2025 | |
| Coopersurgical, INC. | $92.92 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Lupin INC. | $90.08 | 2019 | |
| Exeltis, USA INC. | $75.06 | 2020-2025 | Slynd |
| Alexion Pharmaceuticals, INC. | $59.75 | 2019-2022 | |
| Daiichi Sankyo INC. | $55.82 | 2020-2024 | Injectafer, Vanflyta |
| Minerva Surgical, INC | $47.80 | 2019-2021 | |
| Gynesonics, INC. | $38.39 | 2024-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Shield Therapeutics INC | $35.21 | 2022 | |
| Therapeuticsmd, INC. | $32.12 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.82 | 2019 | |
| Smith+Nephew, INC. | $30.33 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $28.88 | 2025 | Fetal Fibronectin Enzyme Immunoassay |
| Merck Sharp & Dohme LLC | $24.81 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Coloplast Corp | $24.41 | 2025 | |
| Medtronic, INC. | $20.78 | 2024 | Truclear |
| Myovant Sciences INC. | $20.25 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $20.10 | 2023 | Exparel, Zilretta, Iovera |
| Mylan Pharmaceuticals INC. | $19.77 | 2022 | |
| Organon LLC | $19.17 | 2022 | |
| Channel Medsystems, INC. | $18.76 | 2022 | |
| Ethicon US, LLC | $16.78 | 2025 | Enseal |
| Sage Therapeutics, LLC | $16.36 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.24 | 2025 | |
| Lilly USA, LLC | $14.52 | 2025 | Zepbound, Trulicity |
| Evofem Biosciences, INC. | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Pugmire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.